Table IV.
Univariate analyses of factors associated with freedom from progression in the patients with residual PET-positive disease who were selected to receive salvage RT alone (n = 11)
| Characteristic | No Progression (n = 9) | Progression (n = 2) | P |
|---|---|---|---|
| B Symptoms | 3 (33%) | 1 (50%) | 1.0 |
| Bulk | 3 (33%) | 1 (50%) | 1.0 |
| Median Number of ABVD Cycles (Range) | 6 (4–6) | 5 (4–6) | 0.7 |
| Median RT Dose (Range), Gy | 37.8 (30.6–42.2) | 37.8 (36–39.6) | 0.5 |
| Biopsy-Proven Residual Disease | 0 (0%) | 1 (50%) | 0.2 |
| Median Final SUVmax (Range) | 4.9 (3.0–9.6) | 7.1 (2.7–11.5) | 0.8 |
| Median Final MTV (Range), ml | 2.2 (0.9–5.5) | 9.5 (0.1–19) | 0.6 |
| Median Final TLG (Range) | 7.1 (1.0–22) | 37 (0.3–73) | 0.6 |
| Median Final STV (Range), ml | 16 (2.6–87) | 129 (21–236) | 0.5 |
| Median SUVmax Reduction (Range) | 63% (43–77%) | −6% (−87–74%) | 0.6 |
| Median MTV Reduction (Range) | 99% (83–99%) | 96% (92–100%) | 0.9 |
| Median TLG Reduction (Range) | 99% (88–100%) | 95% (90–100%) | 0.5 |
| Median STV Reduction (Range) | 89% (78–95%) | 60% (59–61%) | 0.001 |
ABVD = doxorubicin, bleomycin, vinblastine and dacarbazine
MTV = metabolic tumour volume
RT = radiation therapy
STV = soft tissue volume
SUVmax = maximum standardized uptake value
TLG = total lesion glycolysis